ECSP045200A - ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS - Google Patents

ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS

Info

Publication number
ECSP045200A
ECSP045200A EC2004005200A ECSP045200A ECSP045200A EC SP045200 A ECSP045200 A EC SP045200A EC 2004005200 A EC2004005200 A EC 2004005200A EC SP045200 A ECSP045200 A EC SP045200A EC SP045200 A ECSP045200 A EC SP045200A
Authority
EC
Ecuador
Prior art keywords
alcoxipropanoicos
imidazolil
acids
alkyl
hydrogen
Prior art date
Application number
EC2004005200A
Other languages
Spanish (es)
Inventor
Charlotte Moira Norfor Allerton
David John Bull
Mark Edward Bunnage
Robert John Maguire
John Steele
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201389A external-priority patent/GB0201389D0/en
Priority claimed from GB0202027A external-priority patent/GB0202027D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP045200A publication Critical patent/ECSP045200A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Los compuestos de acuerdo con la fórmula (I) en la que n es 0-3, R1 es alquilo C1-6 opcionalmente sustituido, alquenilo C2-6 o alquinilo C2-6, heterociclo, heterociclo aromático, arilo o hidrógeno y cada uno de R2, R3, R4, R5, R6, R7, R8 y R9 se selecciona independientemente entre hidrógeno y alquilo C1-6 opcionalmente sustituido, o R5 y R8 son una cadena alquileno, son novedosos. Estos compuestos son útiles en el tratamiento de afecciones trombóticas y otras patologías asociadas con la deposición de fibrina.The compounds according to formula (I) in which n is 0-3, R1 is optionally substituted C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, heterocycle, aromatic heterocycle, aryl or hydrogen and each of R2, R3, R4, R5, R6, R7, R8 and R9 are independently selected from hydrogen and optionally substituted C1-6 alkyl, or R5 and R8 are an alkylene chain, they are novel. These compounds are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.

EC2004005200A 2002-01-22 2004-07-22 ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS ECSP045200A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0201389A GB0201389D0 (en) 2002-01-22 2002-01-22 3-(imidazolyl)-2-alkoxypropanoic acids
GB0202027A GB0202027D0 (en) 2002-01-29 2002-01-29 3-(imidazolyl)-2-alkoxypropanoic acids

Publications (1)

Publication Number Publication Date
ECSP045200A true ECSP045200A (en) 2004-08-27

Family

ID=27614792

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005200A ECSP045200A (en) 2002-01-22 2004-07-22 ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS

Country Status (24)

Country Link
EP (1) EP1467731A1 (en)
JP (1) JP2005520811A (en)
KR (1) KR20040077775A (en)
CN (1) CN1620291A (en)
AP (1) AP2004003084A0 (en)
AR (1) AR038197A1 (en)
BR (1) BR0307016A (en)
CA (1) CA2472238A1 (en)
EA (1) EA200400716A1 (en)
EC (1) ECSP045200A (en)
HR (1) HRP20040659A2 (en)
IL (1) IL162677A0 (en)
IS (1) IS7310A (en)
MA (1) MA27167A1 (en)
MX (1) MXPA04006573A (en)
NO (1) NO20043457L (en)
OA (1) OA12756A (en)
PA (1) PA8563501A1 (en)
PE (1) PE20030929A1 (en)
PL (1) PL371487A1 (en)
TN (1) TNSN04121A1 (en)
TW (1) TW200302094A (en)
UY (1) UY27615A1 (en)
WO (1) WO2003061652A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
JP2008536923A (en) * 2005-04-18 2008-09-11 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Use of TAFI inhibitors to enhance myocardial reperfusion and facilitate PCI
EP2361910A4 (en) 2008-10-29 2012-08-01 Taisho Pharmaceutical Co Ltd Compound having tafia inhibitory activity
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
US8642582B2 (en) 2008-12-05 2014-02-04 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXa inhibitors
LT2548871T (en) * 2010-03-18 2017-09-25 Daiichi Sankyo Company, Limited Cycloalkyl-substituted imidazole derivative
CN102884053B (en) * 2010-03-18 2016-03-02 第一三共株式会社 Cyclopropanecarboxylacid acid derivative
CA2914533A1 (en) 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
EP3437641A4 (en) 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited Inflammatory intestinal disease therapeutic agent
TWI802591B (en) 2017-09-14 2023-05-21 日商第一三共股份有限公司 Compound having ring structures

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (en) * 1999-05-03 1999-05-03 Astra Ab New compounds
SK1732003A3 (en) * 2000-08-17 2004-08-03 Pfizer Substituted imidazoles as TAFIa inhibitors

Also Published As

Publication number Publication date
IL162677A0 (en) 2005-11-20
UY27615A1 (en) 2003-08-29
CN1620291A (en) 2005-05-25
WO2003061652A8 (en) 2004-09-10
CA2472238A1 (en) 2003-07-31
JP2005520811A (en) 2005-07-14
MA27167A1 (en) 2005-01-03
OA12756A (en) 2006-07-03
MXPA04006573A (en) 2004-10-04
NO20043457L (en) 2004-08-19
WO2003061652A1 (en) 2003-07-31
IS7310A (en) 2004-06-14
HRP20040659A2 (en) 2004-10-31
TNSN04121A1 (en) 2006-06-01
AR038197A1 (en) 2005-01-05
KR20040077775A (en) 2004-09-06
PA8563501A1 (en) 2004-08-31
PL371487A1 (en) 2005-06-13
EA200400716A1 (en) 2004-12-30
EP1467731A1 (en) 2004-10-20
TW200302094A (en) 2003-08-01
AP2004003084A0 (en) 2004-09-30
BR0307016A (en) 2004-11-03
PE20030929A1 (en) 2003-11-05

Similar Documents

Publication Publication Date Title
NO20005237D0 (en) Heterocyclic substituted amides used as calpain inhibitors
CY1107903T1 (en) ACYLAMINOTHIACEALE PRODUCTS AND THEIR USE AS BETA-AMYLOID INHIBITORS
ES2184280T3 (en) INDOL COMPOUNDS AS COX-2 'INHIBITORS.
PE20050999A1 (en) NOVEL KETOAMIDES WITH CYCLIC P4 AS INHIBITORS OF NS3 SERINE PROTEASE FROM HEPATITIS C VIRUS
NO20071642L (en) N-Benzenesulfonyl-substituted anilino-pyrimidine analogs
PE20040688A1 (en) KINASE INHIBITORS
CR20120152A (en) 3-AMINOPIRROLIDINE DERIVATIVES AS CHEMOCINE RECEPTORS MODULATORS
AR025225A1 (en) PHYSYLOXAZOLIDINONES HETEROCICLIC BICYCLIC REPLACED ANTIBACTERIAL AND PHARMACEUTICAL COMPOSITIONS
NO20065178L (en) Tienopyridinderivater
DE60322877D1 (en) TETRAHYDROPYRANYLCYCLOPENTYLTETRAHYDROISOCHINO LINMODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
ECSP045369A (en) DERIVATIVES OF N- [PHENYL (PIPERIDIN-2-IL) METIL] BENZAMIDA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
PE20050226A1 (en) ARIL-HETEROAROMATIC PRODUCTS AND COMPOSITIONS CONTAINING THEM
CO6150147A2 (en) DERIVED FROM 5,6-BISARIL-2-PIRIDIN-CARBOXAMIDA ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS AS ANTAGONISTS OF UROTENSIN II RECEPTORS
ECSP045200A (en) ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS
ECSP088484A (en) SPIROCYCLIC QUINAZOLINE DERIVATIVES AS PDE7 INHIBITORS
AR042362A1 (en) DERIVATIVES OF 3H-QUINAZOLIN-4-ONA, PROCESS OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PE20060103A1 (en) NEW 5-ACYLINDOLINONES WITH CYCLOALKYL CONTENT AND ITS PREPARATION AS A MEDICINAL PRODUCT
BRPI0508471A (en) difluoroethoxy substituted hydroxy-6-phenylphenanthridines
PE20050231A1 (en) DERIVATIVES OF PIPERIDINIUM AND PYRROLIDINIUM AS ANTAGONISTS OF THE MUSCARINIC M3 RECEPTOR
MXPA04005940A (en) 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases.
CO5690508A2 (en) PESTICIDED MATTER COMPOSITIONS
AR040140A1 (en) CAMPTOTECHINE ESTERS DERIVATIVES IN POSITION 20
AR054414A1 (en) ESPIRO-HYDANTOINE COMPOUNDS REPLACED WITH PIRIDILE. PHARMACEUTICAL COMPOSITIONS.
PE20030611A1 (en) LINEAR BASIC COMPOUNDS THAT HAVE ANTAGONIST ACTIVITY OF NK-2 AND ITS FORMULATIONS
PE20050120A1 (en) KITCHENS WITH A MODIFIED LACTONE RING